{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:45:00Z","timestamp":1785897900901,"version":"3.56.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K09958"],"award-info":[{"award-number":["24K09958"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejps.2026.107592","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T06:52:12Z","timestamp":1782283932000},"page":"107592","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Mirtazapine identified as a preventive agent against cisplatin-induced nephrotoxicity: Integrating in silico, in vitro, and in vivo analyses"],"prefix":"10.1016","volume":"224","author":[{"given":"Ayaka","family":"Hase","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1870-9571","authenticated-orcid":false,"given":"Kenji","family":"Ikemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manami","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhi","family":"Horii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saaya","family":"Azuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Wakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihide","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiro","family":"Yamane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejps.2026.107592_bib0001","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1527-3458.2001.tb00198.x","article-title":"A review of the pharmacological and clinical profile of mirtazapine","volume":"7","author":"Anttila","year":"2001","journal-title":"CNS Drug Rev."},{"issue":"5","key":"10.1016\/j.ejps.2026.107592_bib0002","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1172\/JCI37829","article-title":"Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models","volume":"119","author":"Brooks","year":"2009","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.ejps.2026.107592_bib0003","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10637-020-00903-8","article-title":"Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial","volume":"38","author":"Cao","year":"2020","journal-title":"Invest. New Drugs"},{"issue":"3","key":"10.1016\/j.ejps.2026.107592_bib0004","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2353\/ajpath.2010.090610","article-title":"Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions","volume":"176","author":"Ciarimboli","year":"2010","journal-title":"Am. J. Pathol."},{"issue":"5","key":"10.1016\/j.ejps.2026.107592_bib0005","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1634\/theoncologist.2016-0319","article-title":"A systematic review of strategies to prevent cisplatin-induced nephrotoxicity","volume":"22","author":"Crona","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.ejps.2026.107592_bib0006","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejps.2026.107592_bib0007","article-title":"Novel therapies for nausea and vomiting in advanced illness and supportive cancer care","volume":"18","author":"Davis","year":"2024","journal-title":"Palliat Care Soc Pract"},{"issue":"4","key":"10.1016\/j.ejps.2026.107592_bib0008","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/clpt.2009.139","article-title":"Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity","volume":"86","author":"Filipski","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.ejps.2026.107592_bib0009","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1089\/dna.1997.16.871","article-title":"Cloning and characterization of two human polyspecific organic cation transporters","volume":"16","author":"Gorboulev","year":"1997","journal-title":"DNA Cell Biol."},{"issue":"11","key":"10.1016\/j.ejps.2026.107592_bib0010","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s11095-018-2486-2","article-title":"Selective inhibition on organic cation transporters by carvedilol protects mice from cisplatin-induced nephrotoxicity","volume":"35","author":"Guo","year":"2018","journal-title":"Pharm. Res."},{"issue":"9","key":"10.1016\/j.ejps.2026.107592_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136451","article-title":"Substrate-dependent inhibition of the Human organic cation transporter OCT2: a comparison of Metformin with experimental substrates","volume":"10","author":"Hacker","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ejps.2026.107592_bib0012","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.kint.2020.10.041","article-title":"Diphenhydramine may be a preventive medicine against cisplatin-induced kidney toxicity","volume":"99","author":"Hamano","year":"2021","journal-title":"Kidney Int."},{"issue":"24","key":"10.1016\/j.ejps.2026.107592_bib0013","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.ejps.2026.107592_bib0014","doi-asserted-by":"crossref","first-page":"7902","DOI":"10.1128\/MCB.23.21.7902-7908.2003","article-title":"Deficiency in the organic cation transporters 1 and 2 (Oct1\/Oct2 [Slc22a1\/Slc22a2]) in mice abolishes renal secretion of organic cations","volume":"23","author":"Jonker","year":"2003","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejps.2026.107592_bib0015","doi-asserted-by":"crossref","first-page":"12019","DOI":"10.2147\/DDDT.S576701","article-title":"Drug repurposing as an effective drug discovery strategy: a critical review","volume":"Volume 19","author":"Khzem","year":"2025","journal-title":"Drug Des. Devel. Ther."},{"issue":"7","key":"10.1016\/j.ejps.2026.107592_bib0016","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1248\/bpb.b25-00193","article-title":"Protective effect of palonosetron against cisplatin-induced cytotoxicity via decreased phosphorylation of p38","volume":"48","author":"Kondo","year":"2025","journal-title":"Biol. Pharm. Bull."},{"issue":"1","key":"10.1016\/j.ejps.2026.107592_bib0017","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.taap.2013.08.024","article-title":"Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs)","volume":"273","author":"Li","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"7","key":"10.1016\/j.ejps.2026.107592_bib0018","doi-asserted-by":"crossref","first-page":"454","DOI":"10.2174\/0113894501290296240327081624","article-title":"Drug repurposing using FDA adverse event reporting system (FAERS) database","volume":"25","author":"Morris","year":"2024","journal-title":"Curr. Drug Targets"},{"issue":"2","key":"10.1016\/j.ejps.2026.107592_bib0019","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"issue":"11","key":"10.1016\/j.ejps.2026.107592_bib0020","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.bcp.2010.08.019","article-title":"Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity","volume":"80","author":"Nakamura","year":"2010","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejps.2026.107592_bib0021","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 1","key":"10.1016\/j.ejps.2026.107592_bib0022","first-page":"1???93","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.ejps.2026.107592_bib0023","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5049\/EBP.2014.12.2.55","article-title":"Cisplatin-induced kidney dysfunction and perspectives on improving treatment strategies","volume":"12","author":"Oh","year":"2014","journal-title":"Electrolyte Blood Press"},{"key":"10.1016\/j.ejps.2026.107592_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/967826","article-title":"Pathophysiology of cisplatin-induced acute kidney injury","volume":"2014","author":"Ozkok","year":"2014","journal-title":"Biomed. Res. Int."},{"issue":"6","key":"10.1016\/j.ejps.2026.107592_bib0025","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1172\/JCI200215606","article-title":"TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity","volume":"110","author":"Ramesh","year":"2002","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.ejps.2026.107592_bib0026","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.acthis.2019.01.007","article-title":"Mirtazapine suppresses sterile inflammation through NLRP3-inflammasome in diabetic rat kidney","volume":"121","author":"Sahin","year":"2019","journal-title":"Acta Histochem"},{"issue":"10","key":"10.1016\/j.ejps.2026.107592_bib0027","doi-asserted-by":"crossref","first-page":"484","DOI":"10.31083\/ph.2021.1674","article-title":"Drug repositioning of antipsychotic drugs for cisplatin-induced pica behavior in mice","volume":"76","author":"Sekiguchi","year":"2021","journal-title":"Pharmazie"},{"issue":"3","key":"10.1016\/j.ejps.2026.107592_bib0028","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S1734-1140(12)70855-1","article-title":"Biochemical and histologic study of lethal cisplatin nephrotoxicity prevention by mirtazapine","volume":"64","author":"Sener","year":"2012","journal-title":"Pharmacol. Rep."},{"issue":"9","key":"10.1016\/j.ejps.2026.107592_bib0029","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/WOX.0b013e318186fb3a","article-title":"H1 antihistamines: current status and future directions","volume":"1","author":"Simons","year":"2008","journal-title":"World Allergy Organ J."},{"issue":"5","key":"10.1016\/j.ejps.2026.107592_bib0030","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/clpt.2013.145","article-title":"Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance","volume":"94","author":"Sprowl","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.ejps.2026.107592_bib0031","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3109\/0886022X.2011.623499","article-title":"Effect of mirtazapine on oxidative stress created in rat kidneys by ischemia-reperfusion","volume":"34","author":"Tok","year":"2012","journal-title":"Ren. Fail."},{"issue":"6\u20137","key":"10.1016\/j.ejps.2026.107592_bib0032","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/minf.201000061","article-title":"Best practices for QSAR model development, validation, and exploitation","volume":"29","author":"Tropsha","year":"2010","journal-title":"Mol. Inform."},{"issue":"2","key":"10.1016\/j.ejps.2026.107592_bib0033","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41573-023-00832-0","article-title":"Integrating QSAR modelling and deep learning in drug discovery: the emergence of deep QSAR","volume":"23","author":"Tropsha","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.ejps.2026.107592_bib0034","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/jpet.108.147918","article-title":"Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells","volume":"329","author":"Tsuda","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.ejps.2026.107592_bib0035","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12929-019-0518-9","article-title":"Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity","volume":"26","author":"Volarevic","year":"2019","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ejps.2026.107592_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.896760","article-title":"Repositioning of lansoprazole as a protective agent against cisplatin-induced ototoxicity","volume":"13","author":"Wakai","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"D1","key":"10.1016\/j.ejps.2026.107592_bib0037","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.ejps.2026.107592_bib0038","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1038\/s41598-024-79377-0","article-title":"Identification of dequalinium as a potent inhibitor of human organic cation transporter 2 by machine learning based QSAR model","volume":"15","author":"Yamane","year":"2025","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.ejps.2026.107592_bib0039","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.bcp.2010.11.016","article-title":"Organic cation transporter OCT\/SLC22A and H+\/organic cation antiporter MATE\/SLC47A are key molecules for nephrotoxicity of platinum agents","volume":"81","author":"Yonezawa","year":"2011","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejps.2026.107592_bib0040","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1124\/jpet.106.110346","article-title":"Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family)","volume":"319","author":"Yonezawa","year":"2006","journal-title":"J Pharmacol Exp Ther"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726001661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726001661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:55:06Z","timestamp":1785894906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098726001661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":40,"alternative-id":["S0928098726001661"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107592","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mirtazapine identified as a preventive agent against cisplatin-induced nephrotoxicity: Integrating in silico, in vitro, and in vivo analyses","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107592","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107592"}}